08.26.10
Catalent Pharma Solutions and Sunesis Pharmaceuticals, Inc. entered into a clinical supply services agreement to support Sunesis’ Phase III trial of vosaroxin in first relapse or primary refractory acute myeloid leukemia (AML). Catalent will provide labeling and kitting of the clinical trial materials and will provide supply chain support to clinical sites. The clinical packaging and logistics will be handled in Catalent’s Philadelphia, PA and Schorndorf, Germany facilities.
“As we continue to make important strides towards ensuring that the pivotal Phase III VALOR trial is a well-executed study and work diligently on its timely launch, a key to our progress is our clinical supply partnership with Catalent Pharma Solutions,” said Daniel Swisher, Sunesis' chief executive officer.
“We are pleased to work with Sunesis in providing global clinical supply services support for vosaroxin and the VALOR trial, and we are confident that Catalent’s integrated global solution will help Sunesis advance this important compound,” said Frank Lis, Catalent’s vice president and general manager, Clinical Supply Services.
“As we continue to make important strides towards ensuring that the pivotal Phase III VALOR trial is a well-executed study and work diligently on its timely launch, a key to our progress is our clinical supply partnership with Catalent Pharma Solutions,” said Daniel Swisher, Sunesis' chief executive officer.
“We are pleased to work with Sunesis in providing global clinical supply services support for vosaroxin and the VALOR trial, and we are confident that Catalent’s integrated global solution will help Sunesis advance this important compound,” said Frank Lis, Catalent’s vice president and general manager, Clinical Supply Services.